Skip to content
Screener

CG Oncology CGON Other income, net (Note 6)

Other income, net (Note 6) at other companies

Pfizer logo
PfizerPFE
$3.72B+603%
Johnson & Johnson logo
Johnson & JohnsonJNJ
-$331M-209%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$5.92M-14,332%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$2K+108%
Replimune Group logo
Replimune GroupREPL
-$580K+82.3%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$8.16M-39.8%

Other financials

Income statement

See full
Revenue$1.2M
Operating income-$86.4M-77.3%
Net income-$79.1M-90.8%
EPS (diluted)-$0.90-66.7%

Balance sheet

See full
Cash & equivalents$19.6M+34.3%
Total debt$8.8M+787%
Total equity$1.0B+53.5%
Total assets$1.1B+54.8%

Cash flow

See full
Operating cash flow-$46.4M-66.0%
CapEx$468.0K+3,243%
Free cash flow-$46.9M-67.6%

Valuation

See full
Market cap$6.6B+242%
Enterprise value$6.59B+244%
P/S1,060×-2,439×

Profitability

See full
Operating margin-4,056.2%-1,873pp
Net margin-3,602.7%-1,650pp
FCF margin-2,879.6%-1,307pp

Returns & leverage

See full
Return on equity-26.4%+9.3pp
Debt / equity0.0×
Current ratio22.2×+0.1×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: CG Oncology’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:45 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336918
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss from operations(86,401)(48,741)(152,790)(90,945)
Other income (expense), net
Interest income, net7,3297,31913,61715,066
Other income (expense), net16(4)(85)1
Total other income, net7,3457,31513,53215,067
Net loss and comprehensive loss$(79,056)$(41,426)$(139,258)$(75,878)
Net loss per share, basic and diluted$(0.90)$(0.54)$(1.61)$(1.00)
Weighted average shares of common stock outstanding, basic and diluted88,200,02376,226,82986,369,43776,207,333

Item 1. Financial Statements.

FAQ

What is CG Oncology's other income, net (note 6)?
CG Oncology (CGON) reported other income, net (note 6) of $16K in Q2 2026.
How has CG Oncology's other income, net (note 6) changed year-over-year?
CG Oncology's other income, net (note 6) increased by 500.0% year-over-year, from -$4K to $16K.
What is the long-term trend for CG Oncology's other income, net (note 6)?
Over 2 years (2023 to 2025), CG Oncology's other income, net (note 6) has grown at a 56.6% compound annual growth rate (CAGR), from -$62K to -$152K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about CG Oncology's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude